Site and age effect on chelator utilization at baseline
| Factor site . | Chelator regimen, n (%) . | P* . | |||||
|---|---|---|---|---|---|---|---|
| DFO . | DFX . | DFP . | DFO/ DFP . | DFO/ DFX . | None . | ||
| United States | 50 (21.5) | 147 (63.1) | 4 (1.7) | 13 (5.6) | 10 (4.3) | 9 (3.9) | < .001 |
| Canada | 28 (46.7) | 29 (48.3) | 0 (0.0) | 1 (1.7) | 0 (0.0) | 2 (3.3) | |
| United Kingdom | 3 (8.8) | 16 (47.1) | 5 (14.7) | 8 (23.5) | 0 (0.0) | 2 (5.9) | |
| Age group, y | |||||||
| ≤ 6 | 12 (46.1) | 14 (53.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | .01 |
| 7-16 | 25 (23.8) | 71 (67.6) | 0 (0.0) | 2 (1.9) | 3 (2.9) | 4 (3.8) | |
| > 16 | 44 (22.5) | 107 (54.6) | 9 (4.6) | 20 (10.2) | 7 (3.6) | 9 (4.6) | |
| Factor site . | Chelator regimen, n (%) . | P* . | |||||
|---|---|---|---|---|---|---|---|
| DFO . | DFX . | DFP . | DFO/ DFP . | DFO/ DFX . | None . | ||
| United States | 50 (21.5) | 147 (63.1) | 4 (1.7) | 13 (5.6) | 10 (4.3) | 9 (3.9) | < .001 |
| Canada | 28 (46.7) | 29 (48.3) | 0 (0.0) | 1 (1.7) | 0 (0.0) | 2 (3.3) | |
| United Kingdom | 3 (8.8) | 16 (47.1) | 5 (14.7) | 8 (23.5) | 0 (0.0) | 2 (5.9) | |
| Age group, y | |||||||
| ≤ 6 | 12 (46.1) | 14 (53.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | .01 |
| 7-16 | 25 (23.8) | 71 (67.6) | 0 (0.0) | 2 (1.9) | 3 (2.9) | 4 (3.8) | |
| > 16 | 44 (22.5) | 107 (54.6) | 9 (4.6) | 20 (10.2) | 7 (3.6) | 9 (4.6) | |
For overall comparisons.